Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marvell Technology Inc (MRVL) vs Smith & Nephew plc (SNN) Price & Performance

Marvell Technology IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Marvell Technology Inc vs Smith & Nephew plc — how do they compare? Marvell Technology Inc trades at $217.85 (market cap $190.56B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Marvell Technology Inc is far larger — about 15.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.

MRVLSNN
Market Cap
$190.56B$12.54B
Sector
TechnologyHealth
52-Week High
$316.43$38.70
52-Week Low
$62.31$28.73
Enterprise Value
$191.99B$15.57B
Dividend Yield
0.11%2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marvell Technology Inc

Marvell Technology (MRVL) trades at $221.86, up 6.38% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and revenue growth to $5.77 billion in 2025. Analyst consensus remains strongly bullish with 82% buy ratings and a $275.68 price target, representing 24% upside potential. Recent news highlights Marvell's positioning in AI infrastructure and optical networking leadership.

Marvell presents significant growth potential driven by AI data center expansion and custom chip programs with Microsoft and NVIDIA. However, investors face risks from premium valuations (P/E 72.96), supply chain constraints, and competitive pressure from Broadcom and AMD. The stock's recent volatility and high beta characteristics require careful risk management despite strong institutional support.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.

While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Marvell Technology Inc

Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.

Read more on MRVL

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN